FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387496655> ?p ?o ?g. }

• W4387496655 endingPage "S203" @default.
• W4387496655 startingPage "S202" @default.
• W4387496655 abstract "Traumatic brain injury (TBI) is a highly frequent condition in Brazil, occurring more than 150,000 cases per year, and represents a major risk factor for the development of post-traumatic epilepsy (PTE), with approximately 5% of TBI cases developing PTE. Prevention of TBI-derived PTE is still not available and, therefore, it is necessary to develop new approaches, such as drugs that can act in a preventative way for PTE. Biperiden, an anticholinergic drug, is a promising candidate that has already shown efficacy in murine models of PTE. Neuronal-derived extracellular vesicles (EVs) have the ability to cross the blood-brain barrier, and the potential to transmit peripheral signals originating from the brain. They contain miRNAs which influences the expression of target genes in brain cells and other tissues. This study is a double-blind randomized clinical trial investigating miRNAs in serum EVs in TBI patients associated with biperiden treatment and PTE. The specific objectives were to search for miRNAs related to biperiden administration and to PTE and to identify their target genes and biological pathways. Our study included 37 individuals who suffered TBI. Blood collection was performed 10 days after the trauma and the beginning of the treatment. Of these 37, 18 patients received biperiden, with 3 subjects developing PTE, and 19 received placebo, with 2 developing PTE. The isolation of EVs from the serum of these individuals (miRCURY exosome serum/plasma kit), the characterization of EVs by Nanoparticle Tracking Analysis (NTA) and protein profiling (Exoarray Antibody Array Neuro), extraction of miRNAs from EVs (miRNeasy serum/plasma advanced kit), and library preparation (QIAseq miRNA Library Kit) for next-generation sequencing of the miRNome (Illumina NGS Platform) were performed. Differential expression analysis of these miRNAs, verification of target genes, and pathway enrichment analysis were performed between groups (biperiden x placebo; subjects who developed epilepsy and those who did not). The characterization of EVs with NTA measurements, when comparing the mode of vesicle sizes and the number of particles per mL between the groups, showed no significant differences. The membrane proteins characterization showed that our samples have the presence of proteins from neurons. No differentially expressed miRNA was found between the group that presented PTE as compared to the one that did not. Regarding miRNAs associated with biperiden treatment, miR-9-5p (adjusted-p MiR-9-5p plays an important role in gene regulation, and has been frequently associated with neuroprotection and neurodegeneration, exhibiting differential expression in various neurodegenerative diseases. It also regulates pathways responsible for crucial neuronal processes such as autophagy, hypoxia response, neuroinflammation, and apoptosis, processes involved in epileptogenesis and post-TBI neurological function. This is consistent with our enrichment analysis findings regarding genes that are regulated by miR-9-5p, and suggests that the miR-9-5p downregulation observed in biperiden-treated patients can serve as a biomarker." @default.
• W4387496655 created "2023-10-11" @default.
• W4387496655 creator A5002285722 @default.
• W4387496655 creator A5028788934 @default.
• W4387496655 creator A5030989702 @default.
• W4387496655 creator A5031057097 @default.
• W4387496655 creator A5031808123 @default.
• W4387496655 creator A5031999460 @default.
• W4387496655 creator A5039087395 @default.
• W4387496655 creator A5061343114 @default.
• W4387496655 creator A5069624680 @default.
• W4387496655 creator A5074087902 @default.
• W4387496655 creator A5076106758 @default.
• W4387496655 creator A5082636980 @default.
• W4387496655 creator A5093035808 @default.
• W4387496655 creator A5093035809 @default.
• W4387496655 date "2023-10-01" @default.
• W4387496655 modified "2023-10-18" @default.
• W4387496655 title "T76. DOWNREGULATION OF MIR-9-5P IN PATIENTS TREATED WITH BIPERIDEN AFTER TRAUMATIC BRAIN INJURY" @default.
• W4387496655 doi "https://doi.org/10.1016/j.euroneuro.2023.08.360" @default.
• W4387496655 hasPublicationYear "2023" @default.
• W4387496655 type Work @default.
• W4387496655 citedByCount "0" @default.
• W4387496655 crossrefType "journal-article" @default.
• W4387496655 hasAuthorship W4387496655A5002285722 @default.
• W4387496655 hasAuthorship W4387496655A5028788934 @default.
• W4387496655 hasAuthorship W4387496655A5030989702 @default.
• W4387496655 hasAuthorship W4387496655A5031057097 @default.
• W4387496655 hasAuthorship W4387496655A5031808123 @default.
• W4387496655 hasAuthorship W4387496655A5031999460 @default.
• W4387496655 hasAuthorship W4387496655A5039087395 @default.
• W4387496655 hasAuthorship W4387496655A5061343114 @default.
• W4387496655 hasAuthorship W4387496655A5069624680 @default.
• W4387496655 hasAuthorship W4387496655A5074087902 @default.
• W4387496655 hasAuthorship W4387496655A5076106758 @default.
• W4387496655 hasAuthorship W4387496655A5082636980 @default.
• W4387496655 hasAuthorship W4387496655A5093035808 @default.
• W4387496655 hasAuthorship W4387496655A5093035809 @default.
• W4387496655 hasConcept C104317684 @default.
• W4387496655 hasConcept C118552586 @default.
• W4387496655 hasConcept C126322002 @default.
• W4387496655 hasConcept C145059251 @default.
• W4387496655 hasConcept C20518536 @default.
• W4387496655 hasConcept C2778402981 @default.
• W4387496655 hasConcept C2778689640 @default.
• W4387496655 hasConcept C2781017439 @default.
• W4387496655 hasConcept C2781261824 @default.
• W4387496655 hasConcept C2910745098 @default.
• W4387496655 hasConcept C529278444 @default.
• W4387496655 hasConcept C535046627 @default.
• W4387496655 hasConcept C55493867 @default.
• W4387496655 hasConcept C60644358 @default.
• W4387496655 hasConcept C71924100 @default.
• W4387496655 hasConcept C86803240 @default.
• W4387496655 hasConcept C98274493 @default.
• W4387496655 hasConceptScore W4387496655C104317684 @default.
• W4387496655 hasConceptScore W4387496655C118552586 @default.
• W4387496655 hasConceptScore W4387496655C126322002 @default.
• W4387496655 hasConceptScore W4387496655C145059251 @default.
• W4387496655 hasConceptScore W4387496655C20518536 @default.
• W4387496655 hasConceptScore W4387496655C2778402981 @default.
• W4387496655 hasConceptScore W4387496655C2778689640 @default.
• W4387496655 hasConceptScore W4387496655C2781017439 @default.
• W4387496655 hasConceptScore W4387496655C2781261824 @default.
• W4387496655 hasConceptScore W4387496655C2910745098 @default.
• W4387496655 hasConceptScore W4387496655C529278444 @default.
• W4387496655 hasConceptScore W4387496655C535046627 @default.
• W4387496655 hasConceptScore W4387496655C55493867 @default.
• W4387496655 hasConceptScore W4387496655C60644358 @default.
• W4387496655 hasConceptScore W4387496655C71924100 @default.
• W4387496655 hasConceptScore W4387496655C86803240 @default.
• W4387496655 hasConceptScore W4387496655C98274493 @default.
• W4387496655 hasLocation W43874966551 @default.
• W4387496655 hasOpenAccess W4387496655 @default.
• W4387496655 hasPrimaryLocation W43874966551 @default.
• W4387496655 hasRelatedWork W124780977 @default.
• W4387496655 hasRelatedWork W1672029851 @default.
• W4387496655 hasRelatedWork W2025924280 @default.
• W4387496655 hasRelatedWork W2040078984 @default.
• W4387496655 hasRelatedWork W2356131690 @default.
• W4387496655 hasRelatedWork W2392306180 @default.
• W4387496655 hasRelatedWork W2399544616 @default.
• W4387496655 hasRelatedWork W2465790833 @default.
• W4387496655 hasRelatedWork W2547120245 @default.
• W4387496655 hasRelatedWork W2806153698 @default.
• W4387496655 hasVolume "75" @default.
• W4387496655 isParatext "false" @default.
• W4387496655 isRetracted "false" @default.
• W4387496655 workType "article" @default.